Oculis locks in $57m Series C

Oculis, a developer of ophthalmic treatments, has raised $57 million in Series C financing.

Oculis, a developer of ophthalmic treatments, has raised $57 million in Series C financing. BVCF Management and Hyfinity Investments led the round with participation from other investors that included VI Partners, Wille AG, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund and Silfurberg.

Source: Press Release